0GO Stock Overview
A specialist pharmaceutical company, develops silica nanoparticle delivery systems to enhance the cellular delivery of cancer treatments, gene therapy, and vaccines in the United Kingdom.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
N4 Pharma Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.001 |
| 52 Week High | UK£0.026 |
| 52 Week Low | UK£0.001 |
| Beta | -0.37 |
| 11 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -85.71% |
| 33 Year Change | -98.71% |
| 5 Year Change | n/a |
| Change since IPO | -99.04% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0GO | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -1.9% | -1.4% |
| 1Y | -85.7% | -15.7% | 11.8% |
Return vs Industry: 0GO underperformed the German Pharmaceuticals industry which returned -15.7% over the past year.
Return vs Market: 0GO underperformed the German Market which returned 11.8% over the past year.
Price Volatility
| 0GO volatility | |
|---|---|
| 0GO Average Weekly Movement | 0% |
| Pharmaceuticals Industry Average Movement | 7.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: Data is not available.
Volatility Over Time: Insufficient data to determine 0GO's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1979 | 5 | Nigel Theobald | www.n4pharma.com |
N4 Pharma Plc, a specialist pharmaceutical company, develops silica nanoparticle delivery systems to enhance the cellular delivery of cancer treatments, gene therapy, and vaccines in the United Kingdom. It develops Nuvec, which offers silica nanoparticles with irregular surface structure and polyethyleneimine that traps and protects nucleic acid; and Liptide, a platform to deliver a proprietary siRNA sequence to silence a fibrotic gene for the treatment of glaucoma. The company was incorporated in 1979 and is based in London, the United Kingdom.
N4 Pharma Plc Fundamentals Summary
| 0GO fundamental statistics | |
|---|---|
| Market cap | €3.09m |
| Earnings (TTM) | -€1.30m |
| Revenue (TTM) | €7.04k |
438.0x
P/S Ratio-2.4x
P/E RatioIs 0GO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0GO income statement (TTM) | |
|---|---|
| Revenue | UK£5.86k |
| Cost of Revenue | UK£89.18k |
| Gross Profit | -UK£83.32k |
| Other Expenses | UK£994.73k |
| Earnings | -UK£1.08m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0027 |
| Gross Margin | -1,422.02% |
| Net Profit Margin | -18,399.86% |
| Debt/Equity Ratio | 0% |
How did 0GO perform over the long term?
See historical performance and comparison